Merck Guides FY26 Below Estimates - Update

(RTTNews) - While reporting financial results for the fourth quarter on Tuesday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, initiated its adjusted earnings and net sales guidance for the full-year 2026.

For fiscal 2026, Merck now projects adjusted earnings in a range of $5.00 to $5.15 per share on sales between $65.5 billion and $67.0 billion.

On average, analysts polled expect the company to report earnings of $5.63 per share on sales of $67.58 billion for the year. Analysts' estimates typically exclude special items.

In Tuesday's pre-market trading, MRK is trading on the NYSE at $112.50, down $0.87 or 0.77 percent.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com